Olema Pharmaceuticals (OLMA): Price and Financial Metrics
OLMA Price/Volume Stats
| Current price | $4.46 | 52-week high | $16.62 |
| Prev. close | $4.21 | 52-week low | $2.86 |
| Day low | $4.20 | Volume | 995,785 |
| Day high | $4.59 | Avg. volume | 983,481 |
| 50-day MA | $4.48 | Dividend yield | N/A |
| 200-day MA | $7.53 | Market Cap | 305.16M |
OLMA Stock Price Chart Interactive Chart >
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
OLMA Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OLMA Price Returns
| 1-mo | -3.67% |
| 3-mo | -3.25% |
| 6-mo | -57.32% |
| 1-year | -66.44% |
| 3-year | 18.93% |
| 5-year | N/A |
| YTD | -23.50% |
| 2024 | -58.45% |
| 2023 | 472.65% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |